arrow
E

Eric Assénat

centre hospitalier universitaire de montpellier
H指数:53
被引数:2.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study

瑞戈非尼联合改良吉西他滨-奥沙利铂方案治疗晚期胆道癌。BREGO研究(随机 Ib/II 期)。

2025-06-010
OAAI
Prospective assessment of learning curve and impact of intensive versus progressive training in colonoscopy competence among French residents

对法国住院医师结肠镜操作能力中,强化训练与渐进式训练的学习曲线及影响的预期评估

2025-03-110
OA
Real-life data on biliary tract cancers in France: The nested Amber study from the French ACABi GERCOR PRONOBIL retro-prospective, observational cohort
2025-01-011
OAAI
Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma

开发和验证AI辅助的转录组签名以个性化胰腺导管腺癌患者的辅助化疗

2024-09-011
OAAI
Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients

三联化疗加西妥昔单抗作为延长RAS野生型转移性结直肠癌患者的一线治疗

2024-08-011
OAAI
Absorbed Dose - Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [ 177 Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine

[177 Lu] lu-dotatate治疗胃肠胰神经内分泌肿瘤患者的吸收剂量-反应关系: 向个性化药物迈进了一步

2024-04-186
OAAI
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82)
2023-07-2910
OAAI
Atezolizumab plus bevacizumab in advanced hepatocellular carcinoma after treatment failure with multikinase inhibitors

多激酶抑制剂治疗失败后,阿特珠单抗联合贝伐单抗治疗晚期肝细胞癌

2023-07-014
OAAI
Large, multifocal or portal vein-invading hepatocellular carcinoma (HCC) downstaged by Y90 using personalized dosimetry: safety, pathological results and outcomes after surgery

Y90使用个性化剂量测定法降低大型,多灶性或门静脉侵犯性肝细胞癌 (HCC) 的分期: 安全性,病理学结果和术后结局

2023-06-015
OAAI
Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort
2023-06-0130
OAAI
Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study
2023-02-026
OAAI